TGTX — TG Therapeutics, Inc.

TG Therapeutics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Global Revenue: Approximately $616 million for 2025, with $594 million from U.S. BRIUMVI net sales.
• Q4 Revenue: $183 million, representing a 92% year-over-year growth and 20% sequential growth from Q3.
• Net Income: $447.2 million for the full year, or $2.77 per diluted share, compared to $23.4 million or $0.15 per diluted share in 2024.
• Operating Income: $123 million for 2025, with operating expenses totaling approximately $328 million.
• Cash Position: Over $600 million in current assets, including $200 million in cash and equivalents.

2. Strategic Updates and Business Highlights:

• BRIUMVI Performance: Positioned as a foundational therapy in relapsing multiple sclerosis (RMS) with strong physician adoption and patient retention.
• Clinical Data: 6-year data from ULTIMATE I and II shows nearly 90% of patients were free from confirmed disability progression.
• R&D Initiatives:
  • Phase III ENHANCE study to consolidate BRIUMVI infusions is fully enrolled, with data expected mid-2026.
  • Development of a subcutaneous (subcu) BRIUMVI formulation is underway, with pivotal data anticipated late 2026 or early 2027.
  • Exploration of BRIUMVI in additional autoimmune indications, including Myasthenia Gravis.
• Share Repurchase Program: Completed a $100 million buyback and authorized an additional $100 million, reflecting confidence in long-term value.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: U.S. BRIUMVI net revenue expected between $825 million and $850 million, with total global revenue of $875 million to $900 million.
• Q1 2026 Expectations: Anticipated U.S. revenue growth to approximately $185 million to $190 million, despite typical seasonal headwinds.

4. Challenges and Points of Concern:

• Gross to Net Dynamics: Fluctuations in gross to net revenue are expected, particularly in Q1 due to deductible resets and co-pay program utilization, which may impact revenue timing.
• Competitive Landscape: Ongoing competition from other anti-CD20 therapies, particularly Roche and Novartis, may pressure market share and pricing strategies.
• Investment in Subcu Launch: While incremental costs for the subcu launch are expected to be manageable, there is uncertainty regarding the full commercial strategy and market uptake.

5. Notable Q&A Insights:

• Market Dynamics: Strong growth in new patient starts is noted, but there is caution regarding the pace of growth relative to guidance, with a focus on balancing new versus switch patients.
• DTC Campaign Metrics: Early engagement metrics from the Next In MS campaign have exceeded expectations, indicating strong interest and potential for long-term brand positioning.
• Subcu Market Potential: The subcu market is expected to grow, with the company optimistic about its competitive positioning once launched.
• Sales Force Strategy: The existing sales force is performing well, with no immediate need for refocusing goals, although strategic expansions are ongoing.

Overall, TG Therapeutics reported a robust financial performance for 2025, driven by BRIUMVI's strong market presence and promising pipeline developments, while navigating competitive pressures and market dynamics.